VRXA Veraxa Biotech AG
$0.98▼ -1.97%
Healthcare
Other
Volume 68.9K
Avg Volume (10D) 131.1K
Key Metrics & Fundamentals
Market Cap
$138.58M
P/E Ratio
–
Div Yield
0.00%
52W Range
0.95 - 27.36
% vs 50 MA
-27.85%
% vs 200 MA
-86.12%
RSI-14
35.4
MACD Histogram
+0.0100
Beta (1Y vs SPY)
1.15
Gross Rev
–
Gross Profit
–
EBITDA
–
COGS
–
Operating Exp
–
Operating Income
–
EBIT
–
Pretax Income
–
Net Income
–
Price & Volume History
Loading chart…
Recent News
VERAXA Biotech (VRXA) Expands Human-Relevant Testing Strategy to Advance Antibody-Based Cancer Pipeline
NewMediaWire · Oct 21, 2026 3:00 PM ET
VERAXA Biotech (VRXA) Presents First In Vivo Proof-of-Concept Data for BiTAC-ADC Platform at World ADC Congress
NewMediaWire · Oct 13, 2026 3:30 PM ET
VERAXA Biotech Presents in vivo Proof-of-Concept Data for BiTAC®-ADC Technology at World ADC Congress
GlobeNewswire · Oct 13, 2026 7:00 AM ET
VERAXA Biotech (VRXA) Advances FDA-Aligned Methods to Reduce Animal Testing
NewMediaWire · Oct 7, 2026 3:00 PM ET
This Tiny Biotech Stock Is Down 96% This Year. Can Next-Gen Drug Testing Save It?
Barrons.com · Oct 7, 2026 9:58 AM ET
Veraxa Biotech stock gains on FDA-aligned testing strategy
Investing.com · Oct 7, 2026 9:29 AM ET
VERAXA Biotech Provides Overview on Implementation of FDA-Aligned Human-Relevant Models into R&D Strategy
GlobeNewswire · Oct 7, 2026 7:00 AM ET
VERAXA Biotech (VRXA) Advances Oncology Pipeline as Xlife Sciences Reports First-Half Progress
NewMediaWire · Sep 24, 2026 3:38 PM ET
VERAXA Biotech (VRXA) Builds Oncology Pipeline Around BiTAC Platform, Public-Market Story Enters Next Phase
NewMediaWire · Sep 22, 2026 2:30 PM ET
VERAXA Biotech (VRXA) Adds Capital Markets Veteran as CFO While Advancing BiTAC Oncology Pipeline
NewMediaWire · Sep 18, 2026 3:30 PM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.